Infectious Disease In Vitro Diagnostics Market Report 2026

Infectious Disease In Vitro Diagnostics Market Overview

• Infectious Disease In Vitro Diagnostics market size has reached to $15.1 billion in 2025 • Expected to grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1% • Growth Driver: Surge In Global Prevalence Of Infectious Diseases Fueled The Market Growth Due To Increased Demand For Effective Diagnostic Solutions • Market Trend: Developing Rapid Multi-Pathogen Detection Solutions To Enhance Timely Diagnosis And Expand Point-Of-Care Testing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the infectious disease in vitro diagnostics market include: • Reagents (Segmentation By Product Type) → Expected gain of $18.03 Billion • Instruments (Segmentation By Product Type) → Expected gain of $4.82 Billion • Software And Services (Segmentation By Product Type) → Expected gain of $2.79 Billion

What Is Covered Under Infectious Disease In Vitro Diagnostics Market?

Infectious disease in vitro diagnostics refers to laboratory-based tests performed on samples such as blood, urine, or swabs to detect, identify, and monitor infectious pathogens, including bacteria, viruses, fungi, and parasites. These diagnostics help to provide accurate and timely diagnosis, guide treatment decisions, and support disease surveillance and infection control measures. The main product types of infectious disease in vitro diagnostics are instruments, reagents, and software and services. Instruments refer to tools or devices used to measure and monitor environmental conditions such as air, water, soil, and noise. It utilizes various technologies such as molecular diagnostics, immunoassay, microbiology, hematology, urinalysis, and others. It finds application in methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, respiratory virus, tuberculosis (TB) and drug-resistant TB, gonorrhea, human papillomavirus (HPV), human immunodeficiency virus (HIV), hepatitis C, hepatitis B, and others, serving end-users such as hospitals and clinics, diagnostic laboratories, academic research institutes, and others.

What Is The Infectious Disease In Vitro Diagnostics Market Growth Forecast?

The infectious disease in vitro diagnostics market size is expected to see strong growth in the next few years. It will grow to $21.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to pandemic preparedness initiatives, growth in molecular diagnostics, rising antimicrobial resistance, expansion of diagnostic labs, increased healthcare screening. Major trends in the forecast period include rapid molecular diagnostic adoption, point of care infectious testing, high sensitivity pathogen detection, multiplex diagnostic panels, increased surveillance testing.

What Is The Driver Of The Infectious Disease In Vitro Diagnostics Market?

The increased global prevalence of infectious diseases fueled the growth of the infectious disease in vitro diagnostics market during the historic period. Infectious diseases refer to the individuals affected by bacterial, viral, fungal, or parasitic infections worldwide at a specific point in time, indicating the overall disease burden within populations. Climate change has expanded the habitats of disease-carrying vectors such as mosquitoes, leading to a rise in the global prevalence of infectious diseases. The infectious disease in vitro diagnostics support this trend by providing precise and timely diagnostic tools that enable healthcare providers to identify pathogens, initiate appropriate treatment, and contain outbreaks more effectively. For instance, in October 2024, according to the World Health Organization, a Switzerland-based health authority, approximately 10.8 million people worldwide contracted tuberculosis, with 55% being men, 33% women, and 12% children and adolescents, and individuals living with human immunodeficiency virus (HIV) representing 6.1% of cases. Therefore, the increasing global prevalence of infectious diseases fueled the growth of the infectious disease in vitro diagnostics industry during the historic period.

How Will The Drivers Impact Growth In The Global Infectious Disease In Vitro Diagnostics Market?

• Increasing Funding For Research And Development (Low) – During the forecast period, the increasing funding for research and development is expected to become a key growth driver for the infectious disease in vitro diagnostics market by 2030. Rising investments in research and development serve as a major growth driver for the infectious disease in vitro diagnostics market by facilitating the development of more precise, rapid, and affordable testing solutions. Increased funding promotes advancements in molecular diagnostics, point-of-care testing, and next-generation detection technologies. Stronger r&d support enables companies to respond more effectively to emerging infectious threats and antimicrobial resistance challenges. Both public and private sector funding contribute to faster clinical validation and streamlined regulatory approvals. Collectively, these factors enhance diagnostic efficiency, stimulate market expansion, and support improved global healthcare outcomes. • Integration Of Artificial Intelligence (AI) In Diagnostics (High) – During the forecast period, the integration of artificial intelligence (ai) in diagnostics is expected to emerge as a major factor driving the expansion of the infectious disease in vitro diagnostics market by 2030. The adoption of artificial intelligence (ai) in infectious disease in vitro diagnostics serves as a significant growth catalyst by improving diagnostic speed, accuracy, and operational efficiency. Ai-enabled algorithms facilitate early identification and accurate analysis of complex datasets generated from molecular and serological testing, minimizing human error and reducing turnaround times. The technology also strengthens predictive analytics and real-time outbreak tracking, enhancing disease surveillance and public health management. Furthermore, ai-driven automation optimizes laboratory workflows, lowers operational expenses, and boosts overall testing capacity. • Rising Trend Of Home-Based And Point-Of-Care Testing (High) – During the forecast period, the rising trend of home-based and point-of-care testing is expected to act as a key growth catalyst for the infectious disease in vitro diagnostics market by 2030. The increasing adoption of home-based and point-of-care testing is propelling the infectious disease in vitro diagnostics market by providing rapid, convenient, and accessible testing beyond conventional laboratory settings. Decentralized diagnostic solutions facilitate early disease identification and prompt treatment, helping to curb transmission rates and ease pressure on healthcare systems. Continuous technological advancements have enhanced the accuracy, reliability, and cost-effectiveness of portable diagnostic devices, driving broader utilization.

How Will The Restraints Impact Growth In The Global Infectious Disease In Vitro Diagnostics Market?

• Stringent And Complex Regulatory Approval Processes (Medium) – During the forecast period, the stringent and complex regulatory approval processes act as a major restraint for the infectious disease in vitro diagnostics market because they significantly delay product launches and increase development costs. Manufacturers must comply with varying regional regulations, extensive documentation, and lengthy validation studies before obtaining approval. This slows innovation and discourages smaller companies from entering the market. The high cost and time required to meet regulatory standards also reduce profit margins. As a result, patient access to advanced and rapid diagnostic solutions becomes limited, especially in emerging markets. • High Costs Of Advanced Diagnostic Technologies (High) – During the forecast period, the high costs of advanced diagnostic technologies act as a major restraint in the infectious disease in vitro diagnostics market because they limit accessibility and adoption, especially in low- and middle-income regions. Sophisticated molecular platforms, reagents, and automated analyzers require substantial capital investment and maintenance expenses. These high upfront and operational costs discourage smaller laboratories and healthcare facilities from implementing advanced testing. As a result, testing remains concentrated in well-funded institutions, reducing overall market penetration. This cost barrier ultimately slows the widespread adoption of innovative diagnostic solutions. • Limited Skilled Workforce And Infrastructure Gaps (High) – During the forecast period, the limited skilled workforce and infrastructure gaps act as a major restraint for the infectious disease in vitro diagnostics market by reducing the effective utilization of advanced diagnostic technologies. Many regions face shortages of trained laboratory professionals who can operate and interpret complex diagnostic systems accurately. Inadequate laboratory infrastructure and weak healthcare facilities further limit the deployment of high-end diagnostic equipment. This results in delayed or inaccurate testing outcomes, particularly in rural and resource-limited settings. Consequently, these challenges hinder market expansion and restrict the adoption of advanced infectious disease diagnostic solutions.

Key Players In The Global Infectious Disease In Vitro Diagnostics Market

Major companies operating in the infectious disease in vitro diagnostics market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, Thermo Fisher Scientific Inc., Siemens Healthcare AG, bioMérieux SA, QIAGEN N.V., Becton Dickinson and Company, Hologic Inc., DiaSorin S.p.A., Meridian Bioscience, Quidel Corporation, Revvity Inc., OraSure Technologies Inc., Transasia Bio-Medicals Ltd., Randox Laboratories, Luminex Corporation, Wako Pure Chemical Industries Ltd., Bio-Rad Laboratories Inc., Trivitron Healthcare

Global Infectious Disease In Vitro Diagnostics Market Trends and Insights

Major companies operating in the infectious disease in vitro diagnostics market are focusing on developing innovative products, such as rapid detection of multiple gastrointestinal pathogens, to enable timely diagnosis, improve patient outcomes, and expand point-of-care testing capabilities. Rapid detection of multiple gastrointestinal pathogens refers to diagnostic tests that can quickly identify the presence of several disease-causing microorganisms in the gastrointestinal tract from a single sample. For instance, in June 2024, MP Biomedicals, a US-based provider of a diverse range of products, chemicals, and diagnostics, launched a range of immunochromatographic-based rapid diagnostic kits for gastrointestinal infectious diseases. These enable quick and accurate detection of Helicobacter pylori, Salmonella typhi, and Vibrio cholerae serogroups O1 and O139. These kits feature rapid, point-of-care qualitative detection, versatile sample use (stool, blood, plasma, serum, water, and food), and suitability for both clinical and research settings. Leveraging cutting-edge immunochromatographic technology, they support early diagnosis, monitoring of treatment effectiveness, and confirmation of pathogen eradication, representing a significant advancement in gastrointestinal health diagnostics by combining speed, precision, and broad pathogen coverage.

What Are Latest Mergers And Acquisitions In The Infectious Disease In Vitro Diagnostics Market?

In January 2025, Fremman Capital, a UK-based private equity firm specializing in healthcare and life sciences investments, acquired a majority stake in DIESSE Diagnostica Senese for an undisclosed amount. With this acquisition, Fremman Capital aims to accelerate DIESSE’s international expansion and strengthen its position as a leader in the specialty in vitro diagnostics market by supporting innovation, broadening the product portfolio for autoimmune and infectious disease diagnostics, and enhancing production capacities at DIESSE’s advanced biotech campus, thereby driving long-term sustainable growth. DIESSE Diagnostica Senese is an Italy-based producer of innovative in vitro diagnostics and reagents focused on autoimmunity, infectious diseases, and hematological testing, serving clinical laboratories globally.

What Defines the Infectious Disease In Vitro Diagnostics Market?

The infectious disease in vitro diagnostics market consists of revenues earned by entities by providing services such as serology testing, rapid diagnostic testing, disease surveillance and monitoring, sample collection and processing, and consulting and training services. The market value includes the value of related goods sold by the service provider or included within the service offering. The infectious disease in vitro diagnostics market also includes sales of rapid test kits, culture media, controls and calibrators, molecular sequencing kits, flow cytometry reagents, and point-of-care diagnostic devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Infectious Disease In Vitro Diagnostics Market Report 2026?

The infectious disease in vitro diagnostics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the infectious disease in vitro diagnostics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.